Abstract
A synthetic feline TRIM5-cyclophilin A fusion protein (feTRIMCyp) was generated and transduced into feline cells. feTRIMCyp was highly efficient at preventing infection with human (HIV) and feline (FIV) immunodeficiency virus pseudotypes, and feTRIMCyp-expressing cells resisted productive infection with either FIV-Fca or FIV-Pco. The restriction of FIV infection by feTRIMCyp was reversed by the cyclosporine (Cs) derivatives NIM811 and Debio-025 but less so by Cs itself. FeTRIMCyp and FIV infections of the cat offer a unique opportunity to evaluate TRIMCyp-based approaches to genetic therapy for HIV infection and the treatment of AIDS.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antiviral Restriction Factors
-
Carrier Proteins / chemical synthesis
-
Carrier Proteins / genetics
-
Carrier Proteins / metabolism*
-
Cats
-
Cell Line
-
Cyclophilin A / chemical synthesis
-
Cyclophilin A / genetics
-
Cyclophilin A / metabolism*
-
Disease Models, Animal
-
Feline Acquired Immunodeficiency Syndrome / prevention & control
-
Feline Acquired Immunodeficiency Syndrome / virology*
-
HIV Infections / prevention & control
-
HIV Infections / virology*
-
HIV-1 / physiology*
-
Humans
-
Immunodeficiency Virus, Feline / physiology*
-
Recombinant Fusion Proteins / chemical synthesis
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / metabolism
-
Tripartite Motif Proteins
-
Ubiquitin-Protein Ligases
-
Virus Internalization*
Substances
-
Antiviral Restriction Factors
-
Carrier Proteins
-
Recombinant Fusion Proteins
-
Tripartite Motif Proteins
-
TRIM5 protein, human
-
Ubiquitin-Protein Ligases
-
Cyclophilin A